{
    "clinical_study": {
        "@rank": "163114", 
        "arm_group": [
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single injection of 0.9% saline supplied as a 4 mL unit dose in a 5mL glass syringe"
            }, 
            {
                "arm_group_label": "Hyaluronic Acid and TH", 
                "arm_group_type": "Experimental", 
                "description": "Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 mL unit dose in a 5 mL glass syringe"
            }, 
            {
                "arm_group_label": "Hyaluronic Acid", 
                "arm_group_type": "Active Comparator", 
                "description": "Single injection of sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if a single injection of Cingal into the knee provides\n      safe relief of pain caused by osteoarthritis."
        }, 
        "brief_title": "Cingal Study for Knee Osteoarthritis", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is 40 - 75 years old with a Body Mass Index (BMI)\u2264 40 kg/m2\n\n          -  Subject has Kellgren-Lawrence(K-L)severity grade I, II, or III in the index knee as\n             determined by X-Ray. Contralateral knee: K-L severity grade 0, I, or II.\n\n        Exclusion Criteria:\n\n          -  Subject received an IA injection of Hyaluronic Acid (HA) and/or steroid in either\n             knee within 6 months of signing the ICF.\n\n          -  Subject had an arthroscopy of either knee within 3 months of signing the ICF."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "368", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01891396", 
            "org_study_id": "Cingal 13-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hyaluronic Acid and TH", 
                "intervention_name": "Hyaluronic Acid and TH", 
                "intervention_type": "Device", 
                "other_name": "Cingal"
            }, 
            {
                "arm_group_label": "Hyaluronic Acid", 
                "intervention_name": "Hyaluronic Acid", 
                "intervention_type": "Device", 
                "other_name": "Monovisc"
            }, 
            {
                "arm_group_label": "Saline", 
                "description": "Saline placebo packaged to look identical to comparator syringes.", 
                "intervention_name": "Saline", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hyaluronic Acid", 
                "Triamcinolone Acetonide", 
                "Triamcinolone hexacetonide", 
                "Triamcinolone", 
                "Triamcinolone diacetate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Knee osteoarthritis", 
            "Hyaluronic acid", 
            "HA Injection", 
            "Steroid Injection", 
            "Knee injection"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oakville", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L6K 3T7"
                }, 
                "name": "Deakon Medicine Professional Corporation"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee", 
        "overall_official": {
            "affiliation": "Uzsoki Hospital", 
            "last_name": "Laszlo Hangody, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Hungary: Scientific and Medical Research Council Ethics Committee", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in the WOMAC pain score.", 
            "measure": "Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01891396"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Anika Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anika Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}